Comparative Pharmacology
Head-to-head clinical analysis: VANTRELA ER versus WELLBUTRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VANTRELA ER versus WELLBUTRIN.
VANTRELA ER vs WELLBUTRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norepinephrine reuptake inhibitor and alpha-2 adrenergic receptor agonist; increases norepinephrine and serotonin availability in the prefrontal cortex.
Bupropion is a relatively selective inhibitor of the neuronal reuptake of norepinephrine and dopamine. It does not inhibit monoamine oxidase or the reuptake of serotonin.
VANTRELA ER (cialoxine sodium) 250 mg orally once daily with evening meal; maximum dose 500 mg per day.
Immediate-release: 100 mg orally twice daily initially; after 3 days, increase to 100 mg 3 times daily. Sustained-release: 150 mg orally once daily initially; after 3 days, increase to 150 mg twice daily. Extended-release: 150 mg orally once daily initially; after 3 days, increase to 300 mg once daily.
None Documented
None Documented
Approximately 24 hours (range 20-30 hours) allowing once-daily dosing; steady state reached in 5-7 days.
Terminal half-life: 21 ± 6 hours (hydroxybupropion 24 ± 6 h, threohydrobupropion 37 ± 13 h, erythrohydrobupropion 33 ± 10 h); requires 5-8 days to reach steady state
Primarily renal (70-80% as unchanged drug) with 10-15% biliary/fecal elimination.
Renal (87% as metabolites, 0.5% unchanged); fecal (10%)
Category C
Category C
NDRI Antidepressant
NDRI Antidepressant